Mesenchymal Stem Cells Reduce Left Ventricular Mass in Rats with Doxorubicin-Induced Cardiomyopathy

SUMMARY: Doxorubicin is a drug that used by a majority in the treatment of carcinomas. The most obvious known side effect is cardiomyopathy. Many studies have been carried out to eliminate side effects of the doxorubicin, and stem cell studies have been added in recent years. In this study, it was a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Haydardedeoglu,Ali Evren, Boztok Özgermen,Deva Basak, Yavuz,Orhan
Lenguaje:	English
Publicado:	Sociedad Chilena de Anatomía 2018
Materias:	Adriamycin Heart Morphometry Pluripotent stem cell
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-95022018000100048
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0717-95022018000100048
record_format	dspace
spelling	oai:scielo:S0717-950220180001000482019-09-16Mesenchymal Stem Cells Reduce Left Ventricular Mass in Rats with Doxorubicin-Induced CardiomyopathyHaydardedeoglu,Ali EvrenBoztok Özgermen,Deva BasakYavuz,Orhan Adriamycin Heart Morphometry Pluripotent stem cell SUMMARY: Doxorubicin is a drug that used by a majority in the treatment of carcinomas. The most obvious known side effect is cardiomyopathy. Many studies have been carried out to eliminate side effects of the doxorubicin, and stem cell studies have been added in recent years. In this study, it was aimed to investigate fetal-derived mesenchymal stem cells (F-MSCs) treatment of doxorubicininduced cardiomyopathy by morphological methods. A total of 24 rats which were divided into three separate groups (Control, sham, treatment), each consisting of 8 male rats were used. In sham and treatment group, Adriamycin was administered in a single dose by tail injection to perform cardiotoxicity. In the treatment group, F-MSCs were intra-peritoneally administrated. Then, rats were euthanized and their hearts were photographed at the level of papillary muscle. and thickness, diameters and surface area levels were measured. Left ventricular mass (LVM) and left ventricular mass index (LVMI) were calculated after measurement. The sham group, LVM and LVMI levels were found to significantly lower (p<0.05) than control and treatment group. In the one hand, LVMI levels of rats in treatment group was statistically similar (p>0.05) to control group. Similarly, LVM levels of control and treatment groups were close to each other while this level of sham group was lower. It has been shown that F-MSC administrations in rats with doxorubicin-induced cardiomyopathy have adverse effect on LVM and LVMI values. In addition, the intra-peritoneal MSC administrations may be an alternative to other injection routes such as intra-venous and intra-cardiac administrations.info:eu-repo/semantics/openAccessSociedad Chilena de AnatomíaInternational Journal of Morphology v.36 n.1 20182018-03-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-95022018000100048en10.4067/S0717-95022018000100048
institution	Scielo Chile
collection	Scielo Chile
language	English
topic	Adriamycin Heart Morphometry Pluripotent stem cell
spellingShingle	Adriamycin Heart Morphometry Pluripotent stem cell Haydardedeoglu,Ali Evren Boztok Özgermen,Deva Basak Yavuz,Orhan Mesenchymal Stem Cells Reduce Left Ventricular Mass in Rats with Doxorubicin-Induced Cardiomyopathy
description	SUMMARY: Doxorubicin is a drug that used by a majority in the treatment of carcinomas. The most obvious known side effect is cardiomyopathy. Many studies have been carried out to eliminate side effects of the doxorubicin, and stem cell studies have been added in recent years. In this study, it was aimed to investigate fetal-derived mesenchymal stem cells (F-MSCs) treatment of doxorubicininduced cardiomyopathy by morphological methods. A total of 24 rats which were divided into three separate groups (Control, sham, treatment), each consisting of 8 male rats were used. In sham and treatment group, Adriamycin was administered in a single dose by tail injection to perform cardiotoxicity. In the treatment group, F-MSCs were intra-peritoneally administrated. Then, rats were euthanized and their hearts were photographed at the level of papillary muscle. and thickness, diameters and surface area levels were measured. Left ventricular mass (LVM) and left ventricular mass index (LVMI) were calculated after measurement. The sham group, LVM and LVMI levels were found to significantly lower (p<0.05) than control and treatment group. In the one hand, LVMI levels of rats in treatment group was statistically similar (p>0.05) to control group. Similarly, LVM levels of control and treatment groups were close to each other while this level of sham group was lower. It has been shown that F-MSC administrations in rats with doxorubicin-induced cardiomyopathy have adverse effect on LVM and LVMI values. In addition, the intra-peritoneal MSC administrations may be an alternative to other injection routes such as intra-venous and intra-cardiac administrations.
author	Haydardedeoglu,Ali Evren Boztok Özgermen,Deva Basak Yavuz,Orhan
author_facet	Haydardedeoglu,Ali Evren Boztok Özgermen,Deva Basak Yavuz,Orhan
author_sort	Haydardedeoglu,Ali Evren
title	Mesenchymal Stem Cells Reduce Left Ventricular Mass in Rats with Doxorubicin-Induced Cardiomyopathy
title_short	Mesenchymal Stem Cells Reduce Left Ventricular Mass in Rats with Doxorubicin-Induced Cardiomyopathy
title_full	Mesenchymal Stem Cells Reduce Left Ventricular Mass in Rats with Doxorubicin-Induced Cardiomyopathy
title_fullStr	Mesenchymal Stem Cells Reduce Left Ventricular Mass in Rats with Doxorubicin-Induced Cardiomyopathy
title_full_unstemmed	Mesenchymal Stem Cells Reduce Left Ventricular Mass in Rats with Doxorubicin-Induced Cardiomyopathy
title_sort	mesenchymal stem cells reduce left ventricular mass in rats with doxorubicin-induced cardiomyopathy
publisher	Sociedad Chilena de Anatomía
publishDate	2018
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-95022018000100048
work_keys_str_mv	AT haydardedeoglualievren mesenchymalstemcellsreduceleftventricularmassinratswithdoxorubicininducedcardiomyopathy AT boztokozgermendevabasak mesenchymalstemcellsreduceleftventricularmassinratswithdoxorubicininducedcardiomyopathy AT yavuzorhan mesenchymalstemcellsreduceleftventricularmassinratswithdoxorubicininducedcardiomyopathy
_version_	1718445032232452096

Mesenchymal Stem Cells Reduce Left Ventricular Mass in Rats with Doxorubicin-Induced Cardiomyopathy

Ejemplares similares